Multiple sclerosis and pregnancy: therapeutic considerations
- 25 August 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Zeitschrift für Neurologie
- Vol. 260 (5), 1202-1214
- https://doi.org/10.1007/s00415-012-6653-9
Abstract
For women with multiple sclerosis (MS) who become pregnant, the risks and benefits of ongoing therapy for the health of both the mother and the fetus must be carefully considered. Based on a literature review and our MS center’s standard practices, we provide guidance to aid clinical decision making in the absence of clear evidence-based clinical practice guidelines. Women seeking to achieve pregnancy should generally discontinue disease-modifying therapy use prior to attempting conception. For example, the immunosuppressant mitoxantrone is teratogenic and should be prescribed only with the assurance of effective contraception. Conception should be discouraged for patients on fingolimod, because of the limited information available on human pregnancy outcomes. Current evidence, including data from pregnancy registries for glatiramer acetate (GA), interferon beta-1a (IFNβ-1a), and natalizumab, has not shown specific patterns of malformations suggesting teratogenicity. Pregnancy registry data have not been published for IFNβ-1b. During breastfeeding, intravenous immunoglobulin and corticosteroids are generally safe and may be associated with a reduction in postpartum relapses; however, a washout period is recommended between corticosteroid administration and the resumption of breastfeeding. Clinical data on the use of IFNβ, GA, and natalizumab during lactation are limited. Mitoxantrone is contraindicated during breastfeeding, and fingolimod should be avoided in nursing mothers, because of a lack of data.Keywords
This publication has 63 references indexed in Scilit:
- Transfer of Interferon β-1a into Human BreastmilkBreastfeeding Medicine, 2012
- Long-Term Use of Glatiramer Acetate by 11 Pregnant Women with Multiple SclerosisCNS Drugs, 2010
- Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in FinlandMultiple Sclerosis Journal, 2010
- Economic Burden of Multiple SclerosisPharmacoEconomics, 2010
- Mitoxantrone: benefits and risks in multiple sclerosis patientsNeurological Sciences, 2009
- Effects of natalizumab, an α4 integrin inhibitor, on fertility in male and female guinea pigsBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2009
- Immunomodulation and postpartum relapses in patients with multiple sclerosisTherapeutic Advances in Neurological Disorders, 2009
- EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesAnnals Of The Rheumatic Diseases, 2007
- Cost and health related quality of life consequences of multiple sclerosisMultiple Sclerosis Journal, 2000
- Prednisolone excretion in human milkThe Journal of Pediatrics, 1985